Tirosint Cost in North Dakota 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is Tirosint and Why Does It Cost More Than Generic Levothyroxine?

Tirosint is a brand-name levothyroxine sodium gel capsule manufactured by IBSA Institut Biochimique SA. Its four-ingredient formulation (levothyroxine, gelatin, glycerin, water) eliminates the fillers, dyes, and acacia found in standard tablets, which matters for patients with celiac disease, lactose intolerance, or documented absorption problems. Generic levothyroxine tablets can cost under $10 per month at most North Dakota pharmacies, so the roughly $230 monthly list price of Tirosint reflects the patent-protected, minimal-excipient formulation rather than a higher active-ingredient dose.

The absorption advantage is well-documented. Vita et al. (2014, N=42) demonstrated that levothyroxine in soft-gel capsule form produced significantly better TSH normalization than standard tablets in patients with Helicobacter pylori-related gastritis, a common absorption-impairing condition [1]. A separate study by Fallahi et al. (2016) confirmed that the gel-cap formulation raised free T4 and normalized TSH in patients who had failed tablet therapy despite adequate dosing [2]. The FDA-approved prescribing information for Tirosint notes that the product's bioavailability may differ from levothyroxine tablets and instructs prescribers to recheck TSH 4 to 6 weeks after any formulation switch [3].

Thyroid hormone replacement is one of the most prescribed drug classes in the United States. The American Thyroid Association 2014 guidelines state: "Levothyroxine sodium is the preferred preparation for the treatment of hypothyroidism" and acknowledge that specific patient populations may benefit from alternative formulations when standard tablet absorption is unreliable [4]. That clinical rationale is exactly what distinguishes Tirosint's niche from generic tablets, and it is also what drives the prior-authorization hurdles most North Dakota patients encounter.

Tirosint Cash Price in North Dakota in 2026

The manufacturer list price is approximately $230 per month for a 30-day supply of Tirosint gel capsules. Cash-pay prices at North Dakota retail pharmacies track very close to that list price because Tirosint lacks the generic competition that drives discounting on standard levothyroxine tablets.

GoodRx and similar discount aggregators list Tirosint at $200 to $240 depending on dose strength and pharmacy. Bismarck, Fargo, and Grand Forks pharmacies checked in early 2025 showed prices in the $218 to $232 range for 30 capsules. Smaller rural pharmacies in western North Dakota occasionally price slightly higher due to lower volume purchasing.

Levothyroxine itself has a narrow therapeutic index. The FDA classifies it as such, meaning even small differences in bioavailability between formulations carry clinical weight [3]. That classification also means insurers and Medicaid programs scrutinize substitution requests carefully, which contributes to the access barriers described in later sections.

The HealthRX clinical team uses the following three-question decision framework to help North Dakota patients determine which levothyroxine formulation path makes the most financial sense:

1. Does the patient have documented malabsorption, confirmed celiac disease, H. pylori infection, or a bariatric surgery history? If yes, Tirosint or compounded liquid levothyroxine is clinically appropriate and prior-authorization documentation is stronger.
2. Does the patient carry commercial insurance? If yes, the IBSA savings card likely reduces out-of-pocket cost to near zero.
3. Is the patient on North Dakota Medicaid or uninsured without commercial coverage? If yes, a licensed 503A compounded levothyroxine liquid or gel cap is the most cost-effective route.

North Dakota Medicaid and Tirosint Coverage

North Dakota Medicaid does not cover Tirosint as of 2026. The state's preferred drug list does not include brand-name levothyroxine gel capsules, and no exception pathway has been formally published for this formulation. Patients on ND Medicaid who need a non-tablet levothyroxine formulation face two practical options: pursue a formal prior-authorization exception documenting clinical necessity, or transition to a compounded levothyroxine preparation through a 503A-licensed pharmacy.

Medicaid prior-authorization appeals in North Dakota follow the state's administrative code process. A prescribing clinician must submit clinical documentation showing that generic tablet levothyroxine caused inadequate TSH control or that a specific comorbidity (celiac disease with biopsy confirmation, for example) makes tablet formulations inappropriate. Success rates for such appeals are not publicly published by ND Medicaid, but national data from the Endocrine Society suggest that absorption-related exceptions for levothyroxine gel caps are approvable when documentation is thorough [5].

The Endocrine Society's 2019 clinical practice guideline on hypothyroidism management notes: "In patients with documented absorption issues, liquid or gel-cap levothyroxine formulations may achieve better TSH control than standard tablets" [5]. That direct guideline language is the core of any successful prior-authorization letter for North Dakota Medicaid.

Commercial Insurance Coverage for Tirosint in North Dakota

Most commercial insurance plans available through North Dakota's ACA marketplace and employer-sponsored plans place Tirosint on a non-preferred brand tier, typically Tier 3 or Tier 4, with required prior authorization. Without prior authorization approval, patients pay the full cash price.

Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica (operating in ND) all require prior authorization for brand-name Tirosint. Step therapy is commonly required, meaning the insurer mandates documented failure or intolerance of generic levothyroxine tablets before approving the gel-cap formulation. That step-therapy requirement aligns with FDA bioequivalence standards, which confirm that tablet and gel-cap formulations are not automatically interchangeable without TSH rechecking [3].

Once prior authorization is approved, covered patients may still face a Tier 3 co-pay of $60 to $120 per month depending on their specific plan design. The IBSA savings card (discussed below) can offset that remaining cost for commercially insured patients.

A 2021 analysis published in Thyroid examining levothyroxine formulation switching found that patients who switched from tablets to liquid or gel-cap formulations showed TSH normalization in 73% of cases where tablets had failed, underscoring the clinical rationale insurers must weigh against cost [6].

How the IBSA Savings Card Works in North Dakota

IBSA offers a patient savings program for commercially insured Tirosint patients. Eligible patients may pay as little as $0 per month, subject to program terms and annual maximum benefit limits. The card is not valid for patients covered by Medicare, Medicaid, or any other federal or state government health program, which excludes all North Dakota Medicaid and Medicare beneficiaries.

To use the card, a North Dakota patient must: (1) have a valid Tirosint prescription from a licensed prescriber, (2) carry active commercial insurance, and (3) present the savings card or its digital equivalent at a participating retail pharmacy. The card is processed as a secondary payer after commercial insurance, reducing the remaining co-pay.

The program has income eligibility limits that IBSA updates periodically. Patients should verify current terms directly at the IBSA website or through their pharmacy, because savings card programs can change benefit caps without public notice. Annual maximum benefits typically cap at $1,200 to $2,400, which covers most commercially insured patients' annual Tirosint co-pay exposure.

Patients who are self-pay (no insurance at all) are technically eligible for some manufacturer programs, but IBSA's Tirosint savings card specifically targets commercially insured individuals. Uninsured patients in North Dakota are better served by the compounded levothyroxine route described in the next section.

Compounded Levothyroxine in North Dakota: Legality and Cost

Compounded levothyroxine liquid and gel capsules are legal in North Dakota when prepared by a licensed 503A compounding pharmacy. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound a drug when a prescriber issues a valid patient-specific prescription and a commercially available alternative does not meet the patient's clinical needs [7]. North Dakota follows federal 503A standards and does not impose additional state restrictions that would prohibit levothyroxine compounding.

The FDA's guidance on compounding distinguishes 503A pharmacies (patient-specific, prescription-required, state-licensed) from 503B outsourcing facilities (large-scale, FDA-registered). For individual North Dakota patients, 503A is the applicable pathway [7]. Levothyroxine is not on the FDA's list of drugs that may not be compounded under 503A, so its compounding is permitted as of 2026.

Cost at a 503A compounding pharmacy varies. Cash-pay compounded levothyroxine liquid or gel caps typically run $20 to $60 per month in North Dakota, a substantial reduction from the $230 Tirosint list price. Some compounding pharmacies work with commercial insurers and may bill insurance directly, further reducing patient out-of-pocket cost. Patients on ND Medicaid should ask their prescribing clinician to submit a prior-authorization request specifically for compounded levothyroxine, citing medically necessary formulation requirements.

Bioavailability of compounded levothyroxine preparations has not been studied as rigorously as Tirosint in controlled trials. Jonklaas et al. (2014) noted in the Thyroid journal that "the quality and consistency of compounded thyroid preparations varies by pharmacy and is not guaranteed by FDA oversight in the same manner as approved drugs" [8]. Patients choosing a compounded formulation should use a pharmacy with verified quality controls, ideally one accredited by the Pharmacy Compounding Accreditation Board (PCAB).

Telehealth Prescribing of Tirosint in North Dakota

Tirosint prescriptions can be issued via telehealth in North Dakota. The state permits telehealth prescribing of non-controlled medications without requiring an in-person visit first, provided the prescriber holds a valid North Dakota medical license or a license recognized through the Interstate Medical Licensure Compact [9]. Levothyroxine is not a controlled substance, so no DEA special registration applies.

A telehealth clinician can review lab results (TSH, free T4, and any relevant antibody panels), assess the patient's clinical history, and issue a Tirosint or compounded levothyroxine prescription electronically. The prescription is sent to the patient's preferred pharmacy, including mail-order pharmacies that serve North Dakota addresses.

Telehealth thyroid management requires the same standard of care as in-person care. TSH should be rechecked 4 to 6 weeks after any dose change or formulation switch, per FDA labeling [3], and then annually once stable. The American Association of Clinical Endocrinologists recommends that TSH targets for most hypothyroid adults fall between 0.5 and 2.5 mIU/L, though individual targets may differ based on age and comorbidities [10].

HealthRX clinicians licensed in North Dakota can prescribe Tirosint or compounded levothyroxine through a telehealth visit for clinically appropriate patients. Lab orders can be sent to any Quest, LabCorp, or hospital-affiliated draw site in the state, including locations in Fargo, Bismarck, Minot, Grand Forks, and Williston.

Clinical Rationale: When Is Tirosint or Compounded Liquid Levothyroxine Appropriate?

Not every hypothyroid patient needs Tirosint. Generic levothyroxine tablets work well for most people. The formulation becomes clinically appropriate in a defined set of circumstances.

Absorption-impairing conditions are the primary indication. H. pylori gastritis reduces gastric acid, which impairs levothyroxine tablet dissolution. Vita et al. (2014) showed that switching to gel-cap levothyroxine in H. pylori-positive patients normalized TSH in patients who had been undertreated on tablets at the same dose [1]. Celiac disease similarly reduces intestinal absorptive surface. A study by Collins et al. (2012) found that hypothyroid patients with untreated celiac disease required 49% higher levothyroxine doses than celiac-negative controls to achieve the same TSH target [11].

Bariatric surgery patients, particularly those with Roux-en-Y gastric bypass, show similar absorption impairment. Coupaye et al. (2013) documented that levothyroxine dose requirements increased significantly post-bypass [12]. Liquid or gel-cap formulations, which begin dissolving immediately in gastric fluid rather than requiring tablet disintegration, may reduce this pharmacokinetic variability.

Patients with multiple food or dye allergies may also benefit. Standard levothyroxine tablets contain lactose, acacia, and various colorants. Tirosint's minimal excipient profile reduces allergenic load, though formal allergy trials are limited.

Patients who are simply dissatisfied with their TSH control on tablets, without an identifiable absorption disorder, should address adherence, timing (levothyroxine should be taken 30 to 60 minutes before food on an empty stomach), and drug interactions before concluding that a formulation switch is needed. Calcium carbonate, proton-pump inhibitors, and iron supplements all reduce levothyroxine absorption and are common co-medications in older North Dakota patients [4].

Comparing Total Annual Cost: Tirosint vs. Generic Tablet vs. Compounded

A direct cost comparison across the three formulation options available to North Dakota patients:

Generic levothyroxine tablet (cash pay): Roughly $4 to $10 per month at major retail chains using GoodRx. Annual cost: $48 to $120. Covered on virtually every Medicaid and commercial formulary.

Tirosint brand gel capsule (cash pay, no savings card): Approximately $230 per month. Annual cost: approximately $2,760. Not covered by ND Medicaid.

Tirosint brand gel capsule (commercially insured, with IBSA savings card): After insurance and savings card, $0 per month for eligible patients. Annual cost: $0 to the patient (card covers the gap up to the annual maximum).

Compounded levothyroxine liquid or gel cap (503A, cash pay): Approximately $20 to $60 per month. Annual cost: $240 to $720. May be coverable under commercial insurance with prior authorization; ND Medicaid may cover with documented medical necessity.

The math is clear: commercially insured patients with documented absorption issues have the strongest financial and clinical case for brand Tirosint, because the savings card makes it cost-neutral. Medicaid patients and the uninsured are almost always better served by the compounded route.

Drug Interactions and TSH Monitoring: What North Dakota Patients Need to Know

Levothyroxine absorption is sensitive to several common medications. The FDA labeling for Tirosint specifically lists antacids containing aluminum or magnesium, calcium supplements, iron supplements, and proton-pump inhibitors as agents that reduce levothyroxine absorption when taken simultaneously [3]. Patients should take levothyroxine on an empty stomach and separate it from these agents by at least 4 hours.

Cholestyramine and colestipol bind levothyroxine in the gut and reduce absorption by as much as 30%, according to data cited in the American Thyroid Association 2014 guidelines [4]. Rifampin, carbamazepine, and phenytoin accelerate hepatic clearance of thyroid hormone and may necessitate dose increases. Amiodarone and iodine-containing contrast agents have complex bidirectional effects on thyroid hormone metabolism [4].

TSH monitoring schedule for stable patients on Tirosint or compounded levothyroxine: check TSH at 4 to 6 weeks after any dose or formulation change, then every 6 months for one year, then annually once stable. Pregnancy changes TSH targets substantially. The American Thyroid Association recommends trimester-specific TSH targets during pregnancy (first trimester: 0.1 to 2.5 mIU/L; second trimester: 0.2 to 3.0 mIU/L; third trimester: 0.3 to 3.0 mIU/L) and more frequent monitoring (every 4 weeks in the first half of pregnancy) [13].

North Dakota-Specific Pharmacy and Access Notes

North Dakota has 53 counties and a population of approximately 779,000, with significant rural geography. Patients in western and central ND may have limited local pharmacy options for Tirosint stock. Not all independent rural pharmacies carry Tirosint routinely and may need 3 to 5 business days to order it. Mail-order pharmacies (Express Scripts, CVS Caremark, OptumRx) all carry Tirosint and ship to North Dakota addresses, often with 90-day supplies that reduce per-unit cost slightly.

503A compounding pharmacies licensed in North Dakota include both in-state facilities and out-of-state pharmacies licensed to ship into ND. Federal law allows a 503A pharmacy in another state to compound and ship a patient-specific prescription to a North Dakota patient provided the dispensing pharmacy holds a valid license in that state and complies with North Dakota Board of Pharmacy shipping rules.

The North Dakota Board of Pharmacy maintains a license verification database at www.nodakpharmacy.gov where patients can confirm a compounding pharmacy's active licensure before filling a prescription.